New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BKS;JPM;BLK;GD;NVS;AAPL;VIAB;WDC;RDSA;MPC;VIA From The Last 14 Days
Check below for free stories on BKS;JPM;BLK;GD;NVS;AAPL;VIAB;WDC;RDSA;MPC;VIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 8, 2014
07:26 EDTJPMElsevier Business Intelligence to hold a conference
Subscribe for More Information
07:22 EDTNVSCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
06:24 EDTAAPLApple may develop baseband chpis for iPhones inhouse, DigiTimes says
Subscribe for More Information
06:20 EDTAAPLApple may release iWatch in Q3, DigiTimes reports
Subscribe for More Information
06:07 EDTAAPLMicrosoft investing in 'invisible user interface' technology, WSJ reports
Subscribe for More Information
April 7, 2014
19:57 EDTJPMFederal Reserve announces extension on some CLOs
The Federal Reserve Board announced that it intends to exercise its authority to give banking entities two additional one-year extensions to conform their ownership interests in and sponsorship of certain collateralized loan obligations, or CLOs, covered by section 619 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, commonly referred to as the Volcker rule. Section 619 of the Dodd-Frank Act directed the board to adopt rules for the conformance period and the board previously extended the conformance period for all activities and investments by one year to July 21, 2015. To ensure effective compliance, the board intends to grant banking entities two additional one-year extensions, which together would extend until July 21, 2017, to conform their ownership interests in and sponsorship of CLOs to the statute. Publicly traded companies that may be impacted by the announcement include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
16:01 EDTAAPLOptions Update; April 7, 2014
Subscribe for More Information
14:06 EDTAAPLApple slips to lows of the day, levels to watch
Shares were last at $522.56, just off the session low. At current price, next support is at $517.35. Resistance is at $527.67.
09:34 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:56 EDTJPMJPMorgan, U.K.'S DFID, CDC to invest $20M combined in Novastar Ventures
Subscribe for More Information
08:45 EDTAAPLInvenSense price target raised to $27 from $20 at Pacific Crest
Subscribe for More Information
08:19 EDTVIA, VIAB'Captain America' sequel breaks records with $96.2M debut, LA Times says
Subscribe for More Information
07:51 EDTAAPLApple sent iTV panel samples from Korean display maker, Korea Herald says
Subscribe for More Information
07:37 EDTAAPLApple considered dumping long-time ad agency, WSJ reports
Subscribe for More Information
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:16 EDTAAPLRetailers muscle into competitive mobile payment market, Reuters says
Subscribe for More Information
06:36 EDTAAPLApple's sales force worried about iPhone outlook, Re/code reports
Apple's (AAPL) sales force has been worried about weakness in the iPhone's market share, amid strong competition from Google's (GOOG) Android operating system, a document presented in a court case showed, Re/code reported on Friday. According to the internal Apple document, the only portions of the smartphone market showing growth were large devices costing more than $300 or devices that cost less than $300, the website stated. Reference Link
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 6, 2014
19:01 EDTBLKBlackRock names Robert Goldstein as COO, WSJ says
Subscribe for More Information
17:48 EDTAAPLGoogle set to announce Android TV, The Verge says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use